Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Telegram Restored on Apple App Store After Temporary Removal 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Apple Restores Telegram to App Store After Content Policy Violation 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
SEATTLE, April 05, 2018 -- According to Coherent Market Insights, the global disease control and prevention vaccine market was valued US$ 41.12 Billion in 2017 and is projected to exhibit a CAGR of 12.1% over the forecast period (2017 – 2025).
To know the latest trends and insights prevalent in this market, click the link below: https://www.coherentmarketinsights.com/market-insight/disease-control-and-prevention-vaccine-market-1500
Key Trends and Analysis of the Disease Control and Prevention Vaccine Market:
Increasing research and development activities by manufacturers for introducing new vaccines is expected to drive growth of the market. For instance, in 2014, National Institute of Allergy and Infectious Disease, department of National institute of Health (NIH) collaborating with GlaxoSmithKline developed Ebola vaccine, which is in clinical trial phase in the U.K. Moreover, development of HIV vaccine is major target of vaccine developing companies and institutes, which is expected to be launched over the forecast period, which in turn is expected to drive growth of the disease control and prevention vaccine market. For instance, Johnson & Johnson together with a consortium of global partners initiated the first efficacy study for an investigational mosaic HIV-1 preventive vaccine. Such novel vaccines launches are expected to boost growth of disease control and prevention vaccines market over the forecast period.
Inovio’s HIV vaccine studies are supported by HIV Vaccine Trails Network (HVTN) and NIH’s National Institute of Allergy and Infectious Disease (NIAID). The studies received financial support of US$ 25 million in 2009, followed by US$ 16 million for five year from NIAID. Furthermore, manufacturers of vaccine market are continuously updating their product portfolio by adopting advance research and development strategies.
Request Sample Copy of this Report
Key Market Takeaways:
- Disease control and prevention vaccine market is projected to witness CAGR of 12.1% during the forecast period (2017–2025), owing to increasing vaccination programs by the government to eradicate disease
- High prevalence of infectious disease is expected to propel demand for infectious disease vaccine in the disease control and prevention vaccine market
- Major players operating in the global disease control and prevention vaccine market include GlaxoSmithKline plc (GSK), Merck & Co. Inc., Sanofi, AstraZeneca PLC, Pfizer, Inc., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Astellas Pharma Inc., and Daiichi Sankyo
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave.
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
